These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 9748116)
21. Dose-dense chemotherapy for primary breast cancer. Kümmel S; Rezai M; Kimmig R; Schmid P Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856 [TBL] [Abstract][Full Text] [Related]
22. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Blayney DW; McGuire BW; Cruickshank SE; Johnson DH Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216 [TBL] [Abstract][Full Text] [Related]
23. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Brosteanu O; Hasenclever D; Loeffler M; Diehl V; Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867 [TBL] [Abstract][Full Text] [Related]
24. Mitoxantrone: its development and role in clinical practice. Weiss RB Oncology (Williston Park); 1989 Jun; 3(6):135-41; discussion 141-3, 147-8. PubMed ID: 2701571 [TBL] [Abstract][Full Text] [Related]
25. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. Hryniuk W; Frei E; Wright FA J Clin Oncol; 1998 Sep; 16(9):3137-47. PubMed ID: 9738586 [TBL] [Abstract][Full Text] [Related]
26. Application of theoretical models to chemotherapy protocol design. Goldie JH; Coldman AJ Cancer Treat Rep; 1986 Jan; 70(1):127-31. PubMed ID: 3510731 [TBL] [Abstract][Full Text] [Related]
27. Selecting combinations of chemotherapeutic drugs to maximize dose intensity. Simon R; Korn EL J Biopharm Stat; 1991; 1(2):247-59. PubMed ID: 1844700 [TBL] [Abstract][Full Text] [Related]
28. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy. Carter WH Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084 [No Abstract] [Full Text] [Related]
29. Drug development in solid tumors: personal perspective of Dr. Emil J Freireich's contributions. Carbone PP Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2614-22. PubMed ID: 10068263 [TBL] [Abstract][Full Text] [Related]
30. Multiple testing for a combination drug with two study endpoints. Shao J; Zhang S; Zhao J; Chiang A Stat Med; 2012 Jul; 31(17):1779-90. PubMed ID: 22576824 [TBL] [Abstract][Full Text] [Related]
31. Drug dosage intensity--a panel discussion. McGuire WL; Goldie J; Hryniuk W; Tormey DC Breast Cancer Res Treat; 1987; 9(2):87-100. PubMed ID: 3620720 [TBL] [Abstract][Full Text] [Related]
32. Dosage parameters in chemotherapy of breast cancer. Hryniuk W Breast Dis; 2001; 14():21-30. PubMed ID: 15687633 [TBL] [Abstract][Full Text] [Related]
33. [The current approaches to enhancing the efficacy of antitumor chemotherapy by individual treatment optimization and the selective decrease in the toxic side effects of cytostatics]. Bogush TA; Bogush EA; Stepanov AA Antibiot Khimioter; 2000; 45(1):32-8. PubMed ID: 10690426 [No Abstract] [Full Text] [Related]
34. High-potency preparations of pancreatin. Drug Ther Bull; 1993 Aug; 31(16):63-4. PubMed ID: 8375276 [No Abstract] [Full Text] [Related]
35. Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX. Puzderova B; Belvoncikova P; Grossmannova K; Csaderova L; Labudova M; Fecikova S; Pastorek J; Barathova M Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446271 [TBL] [Abstract][Full Text] [Related]